ARS Pharmaceuticals (SPRY) Fundamentals 2026 — Revenue Analysis | SniperIQ
ARS Pharmaceuticals (SPRY) is a US-listed Healthcare company in Biotechnology with a market capitalization of $603M, trading at $6.08 on the NASDAQ. This SniperIQ fundamentals page covers ARS Pharmaceuticals's valuation, profitability (net margin -200.0%), revenue ($84M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ARS Pharmaceuticals's market cap?
ARS Pharmaceuticals (SPRY) has a market capitalization of approximately $603M, trading at $6.08 on the NASDAQ. Market cap moves with the live share price.
What is ARS Pharmaceuticals's P/E ratio?
ARS Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ARS Pharmaceuticals?
ARS Pharmaceuticals runs a net profit margin of -200.0%, a gross margin of 77.1%, and an operating margin of -204.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ARS Pharmaceuticals generate?
ARS Pharmaceuticals reported revenue of $84M for fiscal year 2025, with net income of -
Does ARS Pharmaceuticals pay a dividend?
ARS Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ARS Pharmaceuticals financially healthy?
ARS Pharmaceuticals carries a debt-to-equity ratio of 1.57x and a current ratio of 4.94x, with a market beta of 0.88. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ARS Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ARS Pharmaceuticals (SPRY) the key facts are: market cap $603M, revenue $84M, 52-week range 6.06-18.63. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ARS Pharmaceuticals's full fundamentals live
Get ARS Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.